Sunday, 16 March 2025
  
Login

Australia's most trusted
source of pharma news

Sunday, 16 March 2025
News

Appeal goes against blockbuster

Posted 24 October 2024 AM

Two patents protecting Bayer's anti-coagulant Xarelto are again in doubt, after an appeal into the decision upholding the patents came down in favour of Sandoz.

On Wednesday the Full Court of Australia found in favour of Sandoz on two grounds of appeal, being that the primary judge erred in finding that patent publication would not have been ascertained within the meaning of s7(3) Patents Act 1990, and that the primary judge applied an incorrect legal test. A third ground of appeal was rejected.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (37)

Clinical & Medical, R&D (14)

Regulatory, Pharmacovigilance & QA (1)

Other (19)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.